We would love to hear your thoughts about our site and services, please take our survey here.
International women’s day
Link to LinkedIn page :
https://www.linkedin.com/feed/update/urn:li:activity:7171986129829646337?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A7171986129829646337%29
For those not on linked in I have cut and pasted the article below .
Scancell Ltd
2,113 followers
10h Edited
💫 On #internationalwomensday2024, this year’s theme is "Invest in women: Accelerate progress“. Scancell Ltd was founded by Lindy Durrant over 20 years ago and she has shared some thoughts on her journey as inspiration to other women embarking on entrepreneurship in biotech to #inspireinclusion.
Female-led start ups and women in senior positions remain less represented across the UK, USA and Europe. Startups led by women are even rarer, and women make up a similarly lower percentage of non-executive directors on boards of biotech companies, reported in an article published in Nature. At Scancell Ltd, we are proud to say women are well represented at senior levels, the board and accross our research teams.
🖥 Learn about Scancell: https://lnkd.in/eHs_3dVy
📑 Read the article: https://lnkd.in/guw6XPN5
#iwd2024womenleadingtheway #iwd2024 #womeninscience #leadership #biotechinnovation
From linked in
Our Research Scientists, Poonam Vaghela and Foram Dave, PhD, will be speaking at the OxfordGlobal Conferences UK – Biologics 2024 conference taking place from 13-15 March 2024 in London, UK. They will be discussing glycan targeting antibodies for T cell redirection and will be presenting preclinical results from reformatting GlyMab® into potential therapeutic modalities for T cell redirection.
✉ Further information: commercial.enquiries@scancell.co.uk
🔎 View the full agenda: https://lnkd.in/eWSWFCH5
#Conference #Immunotherapy #Cancer #immunooncology #immunotherapy #antibodies #antibodydrugconjugates
https://oxfordglobal.com/biologics/events/biologics-2024
This job offer Was posted by Callum Scott LinkedIn page . joined Scancell in February 5 th
Have already posted the full job description:
Here the paragraph that accompanied the advert
“Are you passionate about revolutionising cancer treatment through innovative immunotherapies? If so, then a fantastic opportunity has arisen for a CMC Regulatory Scientist to join a dynamic team which pushes the boundaries of science to make a real impact on patients' lives. We offer a collaborative and supportive environment where your contributions are valued, along with opportunities for professional growth and development. If you are ready to join a forward-thinking company dedicated to making a difference, apply now to become our next CMC Regulatory Scientist! #CMC #Biotech #Immunotherapy #RegulatoryScience”
Dr Scott brings over 15 years of experience in vaccine research and development. Previously, he held the role of Technical Transfer & Formulation Development Manager at UK biotech firm Allergy Therapeutics (AIM: AGY) where he led all CMC (Chemistry, Manufacturing and Controls)/product development activities relating to their VLP Peanut project through Phases 1-3 including IND approvals. Dr Scott holds a PhD in Molecular Microbiology and a BSc in Biochemistry, both from Heriot-Watt University.
CMC Regulatory Scientist
Location: Remote/Oxford Science Park, Permanent, Full-time
Responsible to: Head of Development / Head of Manufacturing
Company Summary
Scancell is an AIM listed biotech company developing novel immunotherapies for the treatment of cancer and infectious disease, with facilities on the Oxford Science Park and at Nottingham University.
Scancell is currently conducting a Phase 2 trial of its ImmunoBody® vaccine in melanoma patients, and a Phase 1/2 first-in-human trial of its Moditope® vaccine in patients with advanced solid tumours.
Scancell currently employs nearly 60 staff, with research scientists located in Nottingham and managerial, translational research, development and administrative staff in Oxford. Scientists working in the Company’s laboratory facilities on the Oxford Science Park support the Company’s clinical trial activities, alongside formulation and analytical development activities for its novel products.
Summary of Post
The CMC Regulatory Scientist will support product development activities, specifically the implementation of regulatory-compliant strategies. The post-holder will be responsible for the technical review and preparation of CMC documents to support regulatory submissions. An applied understanding of product development, including an ability to interpret and apply regulatory guidelines to ongoing CMC activities, is essential. The post holder will also support internal formulation development activities.
Key duties and responsibilities
Leading on the preparation and review of CMC sections relevant to regulatory submissions.
Authoring and reviewing CMC documents (i.e., manufacturing batch-records, specifications, protocols & technical reports) required to support regulatory submissions.
Subject matter expert for products under development.
Positively engage with internal and external stakeholders to ensure the completion of CMC activities required to support regulatory submissions within project timelines.
Develop, maintain, and update a product specification file (PSF).
The CMC Regulatory Scientist will work with external consultants to support the preparation of regulatory submissions.
Routinely review proposed CMC strategies to ensure compliance with the relevant regulatory authority.
Liaise with external vendors and consultants.
Review formulation data and prepare technical reports.
Attend company meetings.
Commit to continued professional development.
Follow company policies and procedures as part of a Quality Management System.
Role requirements
Essential:
An undergraduate degree in a biological or chemical subject.
An understanding of biologic product development/CMC activities (e.g., stability, formulation development, process development, analytical development & manufacturing).
Experience developing and/or manufacturing novel biologics (e.g., recombinants, peptides, and/or antibodies).
Excellent written and communication skills.
Excellent post from Marcus 2 on other board
15:30 marcusl2: 3nobody,
I am very sorry to hear about that disappointment. I am not familiar with the rest of Ultimovacs pipeline but hopefully they do well with the rest of it.
I have been here before myself and took a huge hit when Trovax failed. Only after looking at Scib-1 early success in trials and researching Scancell at length did I fully invest.
Lindy explained why early vaccines failed
Just a reminder about Scib-1;
From Prof Durrant
At this point in this space Ultimovacs is our only competitor in Melanoma and they are using doublet like us.
She thinks their vaccine is inferior as it only targets a single antigen.
That is why we have not moved forward with Scib-2 as it only targets a single antigen (NY-ESO-1) and she thinks there would be an immune escape.
She also thinks if scib/iScib+ works we will beat Moderna hands down as we are off the shelf.
Moderna has told her "if you are correct Lindy then we are in trouble"
SCIB1 incorporates specific epitopes from the proteins gp100 and TRP-2, which were identified from the cloning of T cells from patients who achieved spontaneous recovery from melanoma skin cancers. Both proteins play key roles in the production of melanin in the skin.
iScib+ adds Avidimab plus several more epitopes.
I am certainly hoping that Scancell reaches a valuation multiples of today's.
Advanced unresectable melanoma is a $1.5 billion market on its own.
Wonder how the talk went at the conference:
Because according to the website it offered this :
Cutting-Edge Insights: Access the latest advancements in biomarker discovery, precision medicine, and clinical applications spanning cancer, immunology, neurodegenerative disorders, and cardiovascular biomarkers.
Innovative Immunotherapy: Dive into immune-oncology projects, exploring antibodies, cellular therapy, and immune checkpoint research. Contribute to interactive discussions, share your work, and stay updated on cutting-edge technologies and platforms.
Networking and Collaboration: Connect with industry leaders, researchers, and peers. Foster collaborations, engage in thought-provoking discussions, and explore partnership opportunities.
Professional Development: Enhance your skills with workshops on biomarker data analysis, machine learning, and artificial intelligence applications. Learn best practices and methodologies for biomarker and IO research.
Practical Applications: Discover how research translates into real-world applications. Explore exhibitor showcases, demonstrations, and case studies, gaining insights into the latest tools and technologies.
Personal and Industry Growth: Step out of your comfort zone, engage in interactive roundtables, and contribute to key discussions. Elevate your personal and professional growth within the dynamic fields of biomarker research and immunotherapy.
Https://vulpesinvest.com/wp-content/uploads/2023/09/Scancell-report-final-ver5.0-newformat-3.pdf
This report was 17 th of April 2023
The share price was 18.49 p
When “derisory share price “ mentioned
We now have an excellent management appointed and positive results in trial
The multiple quivers are hitting targets
Maybe 🤔 the chance to pick up shares less than 11 p have vanished and the direction is north bound at speed
Sorry the link doesn’t work
Markus 2
from other board had cut and pasted the info see below
I also add after Thursdays talk I imagine more new will be coming to the fore . A little media coverage would be helpful to start the kindling off and hopefully a healthy on fire share price . It’s been derisory far too long . The drip feed of RnS with a strong management team is everything that was advised in the Vulpes document. I will try to find and repost
It’s “trail blazing “ good luck to one and all
marcusl2: Apr 7 2024 3:00PM
CTMS01. Cancer Vaccines: Ready for Prime Time?
Clinical trial abstracts are under embargo and will be released at 3:00 PM ET on Friday, April 5.
Bermuda
poster at AACR in San Diego in April. Lindy Durrant is down to present in the 'Cancer Vaccines: Ready for Prime Time?' session and seems that we'll be getting the SCIB1 results.
'CT024 - A DNA plasmid melanoma cancer vaccine, SCIB1, combined with nivolumab + ipilimumab in patients with advanced unresectable melanoma: Efficacy and safety results from the open-label Phase 2 SCOPE Trial'
Https://www.abstractsonline.com/pp8/#!/20272/session/663
Does this link work
Embargo is lifted on my birthday 5 th of April
From
21:38 marcusl2: GlyMab® and AvidiMab® platforms provide potential out licensing opportunities with active discussions ongoing with pharmaceutical and biotech companies (at least 4). We know one of these is correct.
Genmab
Biontech
BMS, Pfizer/Seagen
Eli Lilly, Roche/Genentech
Https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/kaira-et-al-2022.pdf
Https://clinicaltrials.ucsf.edu/trial/NCT04993677
Seagen trial is it the one using Avidimab or am I just imagining that ?
It’s either way interesting trial
Please could someone let me know
Link to full event - immune-oncology-conference-London 7-8 th of March
https://events.marketsandmarkets.com/immuno-oncology-conference-london/#agenda
Just wondering why it’s not mentioned ceo of Scancell
A novel redirecting antibody targeting SCLC
Lindy Durrant, Professor, Cancer Immunotherapy, University of Nottingham, UK 14:45 - 15:15
A little reminder
EuroBiotech Report—Novartis, Immunocore-Scancell, Wren A round, Novo and BioNTech
This was from fierce pharma 2019
https://www.fiercebiotech.com/biotech/eurobiotech-report-novartis-immunocore-scancell-wren-a-round-novo-and-biontech
This was on linked in
We would like to say a BIG thank you to the organisations that supported this year's Melanoma Patient Conference! Our event would not be possible without our brilliant sponsors.
A special shout out to the extremely generous companies who donated products for this year's delegate goodie bags. 💙
University of Oxford
Bristol Myers Squibb
Scancell Ltd
Novartis
Pierre Fabre Group
Immunocore
Skcin - The Karen Clifford Skin Cancer Charity
Hello Sunday
Little Soap Company - BCorp™
Popcorn Kitchen Ltd
The Ginger People® / Ginger People Group
Ultra Violette Skincare
Nursem
La Roche-Posay Laboratoire Dermatologique
Pip Organic
Ego Pharmaceuticals
From Marcus 2 other board
University of Hong Kong (HKUMed), found that PD-1-enhanced DNA vaccination can induce sustained virus-specific CD8+ T cell immunity in an AIDS monkey model
https://www.globaltimes.cn/page/202403/1307969.shtml
9.25 prof Sarah Danson author of a recent poster
Giving updates on recent melanoma trials
https://melanomafocus.org/wp-content/uploads/2024/02/MPC24-Virtual-Brochure-2024-1.pdf